In an environment where the majority of the MedTech stocks have been bashed relentlessly in the past month, Qiagen has been an exception. A takeover bid by Thermo Fisher took the scrip to lifetime highs in early March 2020. Moreover, the spread of COVID-19 globally, which opened a window of opportunity for the in-vitro diagnostics firm, further bolstered the momentum. Ergo, we view Qiagen as a good cash proxy in the current volatile environment.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
A safe bet
In an environment where the majority of the MedTech stocks have been bashed relentlessly in the past month, Qiagen has been an exception. A takeover bid by Thermo Fisher took the scrip to lifetime highs in early March 2020. Moreover, the spread of COVID-19 globally, which opened a window of opportunity for the in-vitro diagnostics firm, further bolstered the momentum. Ergo, we view Qiagen as a good cash proxy in the current volatile environment.